Navigation Links
MRI before surgery leads to better-adapted treatment for breast cancer
Date:4/16/2008

Berlin, Germany: The early use of magnetic resonance imaging (MRI) in women diagnosed with breast cancer can often lead to a better adapted surgical approach to the tumour, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today (Wednesday April 16). Dr. David Martinez-Cecilia, a surgeon from the General Surgery Service, directed by Prof. Rufian-Pea, in the Hospital Universitario Reina Sofia, Cordoba, Spain, said that this technique should become standard in determining the stage of the tumour before any operation.

Dr. Martinez-Cecilia and his team studied 249 patients who were undergoing surgery for breast cancer, and carried out routine MRI as soon as a biopsy showed malignancy. If additional lesions were discovered, a further biopsy was carried out on them.

Using MRI, we found 20 additional malignant lesions in 18 patients, he said, and that meant that for 15 patients we were able to change the surgical treatment to one which took care of all the tumours, as opposed to the single one that had originally been diagnosed. Three patients needed surgery in both breasts, one required a second lumpectomy in the same breast, and 11 changed from lumpectomy to mastectomy. The surgical treatment also changed in those patients where the MRI showed up a larger tumour than that which was originally identified; 16 other patients changed from lumpectomy to mastectomy, and one from lumpectomy to quadrantectomy, a partial mastectomy where the tumour and some surrounding breast tissue is removed to be sure that the margins around the tumour are cancer-free.

The scientists then carried out a retrospective analysis of the surgical outcomes. We found that the changes in surgical treatment had been beneficial in 22 patients (9%), non beneficial in 6 patients (2.4%), and uncertain in 4 patients (1.6%), said Dr. Martinez-Cecilia. The results also showed us that MRI is the best imaging technique for measuring tumour size, better than mammography or ultrasound. MRI is being used more frequently in breast cancer pre-operative staging these days, and we thought it was important to validate its efficacy.

MRI is expensive, but with results such as these it should be used as widely as possible pre-surgery, say the scientists. It will not only improve the surgical treatment, which was our main aim, but in the long run it will probably reduce costs to healthcare systems by allowing us to identify exactly what needs to be treated, and in what way, to avoid possible recurrences of the cancer and the costs associated with its treatment, said Dr. Martinez-Cecilia. We will continue working prospectively with this issue as we would like to see MRI become a standard preoperative treatment for breast cancer, along with biopsy, mammography, and ultrasound.


'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. MRI finds breast cancer before it becomes dangerous
2. Removing Ovaries Before Menopause Leads to Memory, Movement Troubles
3. Underage drinking starts before adolescence
4. Fat Builds Up in Hearts Before Diabetes Onset
5. Meth Project Chairman Testifies Before U.S. Senate Finance Committee
6. Take Care of Your Heart Before and After Problems
7. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
8. American Society of Transplantations Past President Testifies Before Congress at Forum on Organ Donation
9. Kaiser Permanente Study Shows One in Seven Women are Depressed Before, During, or After Pregnancy
10. Guidelines help patients reduce risk of cardiac event before surgery
11. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: